INDSWFTLAB Ind-Swift Laboratories Q1 FY27 results (Apr–Jun 2026) and concall
Ind-Swift Laboratories Limited reported a strong Q1 FY27, with significant growth in operating income and a substantial expansion in EBITDA and PAT margins. The company successfully commercialized key CDMO partnerships and launched new products, driving a meaningful shift towards high-margin export-oriented own-brands. Management expressed confidence in sustaining this growth trajectory and achieving higher margins, while also outlining capital deployment plans for future expansion and R&D.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
Q1 FY27: revenue up 24.8%, net profit up 177.8% against the same quarter last year.
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 12 | 129 | 138 | 153 | 153 +1175% | 151 +17% | 170 +23% | 191 +25% |
| EBITDA | -12 | -7 | -9 | 4 | 1 +108% | 4 +157% | 21 +333% | 33 +725% |
| Net profit | 0 | -5 | 222 | 9 | 8 | 10 +300% | 15 −93% | 25 +178% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
